Cargando…
Temporal volume increase after reduction of masseteric hypertrophy utilizing incobotulinumtoxin type A
BACKGROUND: Treating the lower face with neuromodulators and targeting the masseter muscle can reduce masseteric hypertrophy but can also change the facial shape. A novel observation after the treatment of the masseter muscle with incobotulinumtoxin Type A was the increase in temporal volume. AIM: O...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317345/ https://www.ncbi.nlm.nih.gov/pubmed/32338450 http://dx.doi.org/10.1111/jocd.13434 |
_version_ | 1783550605662355456 |
---|---|
author | Nikolis, Andreas Enright, Kaitlyn M. Rudolph, Christina Cotofana, Sebastian |
author_facet | Nikolis, Andreas Enright, Kaitlyn M. Rudolph, Christina Cotofana, Sebastian |
author_sort | Nikolis, Andreas |
collection | PubMed |
description | BACKGROUND: Treating the lower face with neuromodulators and targeting the masseter muscle can reduce masseteric hypertrophy but can also change the facial shape. A novel observation after the treatment of the masseter muscle with incobotulinumtoxin Type A was the increase in temporal volume. AIM: Objectively assess temporal volume increase following treatment of masseteric hypertrophy using incobotulinumtoxin Type A. METHODS: Nine female patients with a mean age of 35.11 years ± 9.1 [Asian (11.1%) and Caucasian (88.9%)] were treated with incobotulinumtoxin Type A for masseteric hypertrophy. Masseteric prominence and temporal volume were assessed by two independent raters, and temporal fossa volume was measured via 3‐dimensional volumetric imaging. RESULTS: Independent of the neuromodulator injection technique (ie, single‐injection versus multi‐injection), a reduction in masseteric hypertrophy occurred represented by a decrease in the masseter prominence scale. In addition, the treatment resulted in a significant improvement of the temporal volume scale and an increase in the measured volume of the temporal fossa. None of the presented measurements were statistically significantly different between the two utilized injection techniques. CONCLUSIONS: This study supports using a full‐face approach when performing aesthetic treatments. Anatomical concepts can help to guide treatments: the compensatory increase in temporalis function after masseter muscle treatment resulted in an increased in temporal fossa volume. The findings presented herein should not be considered as a new concept for treating the temporal fossa but rather as an additional possibility for increasing the temporal volume. |
format | Online Article Text |
id | pubmed-7317345 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73173452020-06-30 Temporal volume increase after reduction of masseteric hypertrophy utilizing incobotulinumtoxin type A Nikolis, Andreas Enright, Kaitlyn M. Rudolph, Christina Cotofana, Sebastian J Cosmet Dermatol Injectable Articles BACKGROUND: Treating the lower face with neuromodulators and targeting the masseter muscle can reduce masseteric hypertrophy but can also change the facial shape. A novel observation after the treatment of the masseter muscle with incobotulinumtoxin Type A was the increase in temporal volume. AIM: Objectively assess temporal volume increase following treatment of masseteric hypertrophy using incobotulinumtoxin Type A. METHODS: Nine female patients with a mean age of 35.11 years ± 9.1 [Asian (11.1%) and Caucasian (88.9%)] were treated with incobotulinumtoxin Type A for masseteric hypertrophy. Masseteric prominence and temporal volume were assessed by two independent raters, and temporal fossa volume was measured via 3‐dimensional volumetric imaging. RESULTS: Independent of the neuromodulator injection technique (ie, single‐injection versus multi‐injection), a reduction in masseteric hypertrophy occurred represented by a decrease in the masseter prominence scale. In addition, the treatment resulted in a significant improvement of the temporal volume scale and an increase in the measured volume of the temporal fossa. None of the presented measurements were statistically significantly different between the two utilized injection techniques. CONCLUSIONS: This study supports using a full‐face approach when performing aesthetic treatments. Anatomical concepts can help to guide treatments: the compensatory increase in temporalis function after masseter muscle treatment resulted in an increased in temporal fossa volume. The findings presented herein should not be considered as a new concept for treating the temporal fossa but rather as an additional possibility for increasing the temporal volume. John Wiley and Sons Inc. 2020-04-27 2020-06 /pmc/articles/PMC7317345/ /pubmed/32338450 http://dx.doi.org/10.1111/jocd.13434 Text en © 2020 The Authors. Journal of Cosmetic Dermatology published by Wiley Periodicals LLC This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Injectable Articles Nikolis, Andreas Enright, Kaitlyn M. Rudolph, Christina Cotofana, Sebastian Temporal volume increase after reduction of masseteric hypertrophy utilizing incobotulinumtoxin type A |
title | Temporal volume increase after reduction of masseteric hypertrophy utilizing incobotulinumtoxin type A |
title_full | Temporal volume increase after reduction of masseteric hypertrophy utilizing incobotulinumtoxin type A |
title_fullStr | Temporal volume increase after reduction of masseteric hypertrophy utilizing incobotulinumtoxin type A |
title_full_unstemmed | Temporal volume increase after reduction of masseteric hypertrophy utilizing incobotulinumtoxin type A |
title_short | Temporal volume increase after reduction of masseteric hypertrophy utilizing incobotulinumtoxin type A |
title_sort | temporal volume increase after reduction of masseteric hypertrophy utilizing incobotulinumtoxin type a |
topic | Injectable Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317345/ https://www.ncbi.nlm.nih.gov/pubmed/32338450 http://dx.doi.org/10.1111/jocd.13434 |
work_keys_str_mv | AT nikolisandreas temporalvolumeincreaseafterreductionofmasseterichypertrophyutilizingincobotulinumtoxintypea AT enrightkaitlynm temporalvolumeincreaseafterreductionofmasseterichypertrophyutilizingincobotulinumtoxintypea AT rudolphchristina temporalvolumeincreaseafterreductionofmasseterichypertrophyutilizingincobotulinumtoxintypea AT cotofanasebastian temporalvolumeincreaseafterreductionofmasseterichypertrophyutilizingincobotulinumtoxintypea |